X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    New Delivery Path Brings To Light Efficacy of Immunotherapy

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    New Delivery Path Brings To Light Efficacy of Immunotherapy

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Market Moves

New upper extremity standard biopsy sites for diagnosis of small fiber neuropathy

Yuvraj_pawp by Yuvraj_pawp
6th August 2014
in Market Moves

Therapath LLC (www.Therapath.com),a leader in neuropathology laboratory services, has established normative values for two upper limb body sites that can now be used to evaluate 3mm punch skin biopsy specimens for Epidermal Nerve Fiber Density (ENFD) and Sweat Gland Nerve Fiber Density (SGNFD). The additional body sites were determined in an IRB approved clinical study of normal adult subjects. The new biopsy sites are defined as the Proximal Arm (Lateral surface midway between the shoulder (acromion) and the elbow) and the Distal Arm (Upper (hairy or dorsal) surface of the forearm, 5 cm above the wrist). These new sites complement the existing standardized biopsy sites at the proximal thigh, distal leg (calf) and dorsal foot. The punch skin biopsy with enumeration of the epidermal nerve fiber density is a reliable and efficient technique to assess the diagnosis of small fiber neuropathy (Joint Task Force or EFNS and PNS, J Periph Nerv Syst 2010).

 

Several studies have recently reported a decrease in epidermal nerve fiber density in a subset of patients with fibromyalgia (Oaklander et al, Pain 2013; Caro and Winter, Arthritis Rheumatol 2014; Giannoccaro, et all, Muscle Nerve 2014) concluding that skin biopsy should be considered in the diagnostic work-up of Fibromyalgia to search for Small Fiber Neuropathy. The availability of the new standard biopsy sites will enable physicians diagnose small fiber neuropathy in patients whose symptoms are confined to the upper extremities.

 

Additionally, Therapath completed analysis on the effect of age and gender on normative values for ENFD and SGNFD at all standardized biopsy sites. Therapath will use these values for diagnosis of small fiber neuropathy.

 

About Therapath Neuropathology:

 

Therapath Neuropathology, founded in 2004, is a College of American Pathology accredited (CAP) and CLIA licensed specialized laboratory. The medical team are board certified in neuropathology, academically trained and extensively published. Therapath’s focus is on research and development in the testing services for muscle biopsy, nerve biopsy with teased fiber analysis, ocular (including optic neurotis), skin epidermal nerve fiber density, sweat gland nerve fiber density, skin biopsy for CADASIL and other storage disorders as well as brain/spinal cord specimens. Therapath serves hospitals, private practitioners, reference laboratories, pharmaceutical industry, and researchers throughout all 50 states and worldwide including; Australia, Brazil, Canada, China, England, Germany, Greece, Hong Kong, Israel, Italy, Japan, Mexico, the Netherlands, and Saudi Arabia.

Previous Post

AMRI ANNOUNCES SECOND QUARTER 2014 RESULTS

Next Post

Orexigen Therapeutics Reports Corporate and Financial Results for the Second Quarter Ended June 30, 2014

Related Posts

Featured

SVB Collapse And Its Implications On Biotechnology Sector

18th March 2023
Featured

US President Looks To Double The Drugs For Price Negotiation

18th March 2023
$118bn Sales By 2026 Is What Japanese Pharma Can Expect
Featured

$118bn Sales By 2026 Is What Japanese Pharma Can Expect

2nd March 2023
Featured

Bioavailability Enhancement Market Projects CAGR of 11%

28th February 2023
Grünenthal to buy NebidoTM testosterone treatment from Bayer for €500m
Market Moves

Grünenthal to buy NebidoTM testosterone treatment from Bayer for €500m

18th July 2022
Could The Long Deckline In Biotechnology M&A Be Ending
Featured

Could The Long Deckline In Biotechnology M&A Be Ending

16th July 2022
Next Post

Orexigen Therapeutics Reports Corporate and Financial Results for the Second Quarter Ended June 30, 2014

Latest News

Drug Development

New Delivery Path Brings To Light Efficacy of Immunotherapy

1st April 2023
Cathay Cargo signs global airline partnership with Tower Cold Chain
Packaging & Logistic

Cathay Cargo signs global airline partnership with Tower Cold Chain

31st March 2023
Quotient Sciences completes integration of drug substance into Translational Pharmaceutics Platform
Facilities & Operation

£277m Funding Set To Benefit UK Life Sciences Manufacturing

31st March 2023
Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In